Advances in genomics have deepened our understanding of the biology of acute
lymphoblastic leukemia (ALL), defined novel molecular leukemia subtypes, discovered new …

Background: Various studies have reported that IKZF1 deletion (IKZF1-d) is a poor
prognostic factor for acute lymphoblastic leukemia (ALL) patients, however they do not …

Improved personalized adjustment of primary therapy to the perceived risk of relapse by
using new prognostic markers for treatment stratification may be beneficial to patients with …

Background Despite best current therapy, up to 20% of pediatric patients with acute
lymphoblastic leukemia (ALL) have a relapse. Recent genomewide analyses have identified …

Transcription factor IKZF1 (IKAROS) acts as a critical regulator of lymphoid differentiation
and is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia. IKZF1 …

B-precursor acute lymphoblastic leukemia (B-ALL) is the most common childhood
malignancy and remains a leading cause of death in children and young adults. Current …

Alterations in the IKZF1 gene are associated with poor prognosis in pediatric B‐cell acute
lymphoblastic leukemia (B‐ALL). We examined the relationship between IKZF1 alterations …

The IKAROS family zinc finger 1 (IKZF1) gene is frequently altered in adults with B cell acute
lymphoblastic leukemia (ALL). Although many studies have indicated that IKZF1 alterations …

Abstract IKZF1 (IKAROS family Zinc Finger 1) alteration is an essential regulator of both T-
and B-cell lineage specification with leukemogenic potential. IKZF1 deletion have been …

Background Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with
common B-cell acute lymphoblastic leukemia. Methods One hundred sixty-five consecutive …